FOLH1 and prostate cancer: In recognition of all the pros and cons of the PSMA-targeted radionuclide therapies, The Prostate Cancer Foundation convened in 2017 a PSMA-Directed Radionuclide Scientific Working Group to discuss the potential for using PSMA-targeted radionuclide agents for the treatment of advanced prostate cancer and to define the future studies and clinical trials necessary for validating and optimizing the use of these.